The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
Open accessAbstract
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with autoantibodies to anti-aquaporin-4 (AQP4-IgG) in approximately two thirds of patients. Interleukin-6 is involved in the pathogenesis of the disorder. Satralizumab is a humanized monoclonal antibody targeting the interleukin-6 receptor. The efficacy of satralizumab added to immunosuppressant treatment in patients with NMOSD is unclear. METHODS: In a phase 3, randomized, double-blind, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, patients with NMOSD who were seropositive or seronegative for AQP4-IgG to receive either satralizumab, at a dose of 120 mg, or placebo, administered subcutaneously at weeks 0, 2, and 4 and every 4 weeks thereafter, added to stable immunosuppressant treatment. The primary end point was the first protocol-defined relapse in a time-to-event analysis. Key secondary end points were the change from baseline to week 24 in the visual-analogue scale (VAS) pain score (range, 0 to 100, with higher scores indicating more pain) and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score (range, 0 to 52, with lower scores indicating more fatigue). Safety was also assessed. RESULTS: A total of 83 patients were enrolled, with 41 assigned to the satralizumab group and 42 to the placebo group. The median treatment duration with satralizumab in the double-blind period was 107.4 weeks. Relapse occurred in 8 patients (20%) receiving satralizumab and in 18 (43%) receiving placebo (hazard ratio, 0.38; 95% confidence interval [CI], 0.16 to 0.88). Multiple imputation for censored data resulted in hazard ratios ranging from 0.34 to 0.44 (with corresponding P values of 0.01 to 0.04). Among 55 AQP4-IgG-seropositive patients, relapse occurred in 11% of those in the satralizumab group and in 43% of those in the placebo group (hazard ratio, 0.21; 95% CI, 0.06 to 0.75); among 28 AQP4-IgG-seronegative patients, relapse occurred in 36% and 43%, respectively (hazard ratio, 0.66; 95% CI, 0.20 to 2.24). The between-group difference in the change in the mean VAS pain score was 4.08 (95% CI, -8.44 to 16.61); the between-group difference in the change in the mean FACIT-F score was -3.10 (95% CI, -8.38 to 2.18). The rates of serious adverse events and infections did not differ between groups. CONCLUSIONS: Among patients with NMOSD, satralizumab added to immunosuppressant treatment led to a lower risk of relapse than placebo but did not differ from placebo in its effect on pain or fatigue. (Funded by Chugai Pharmaceutical; ClinicalTrials.gov number, NCT02028884.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
Self-citationRevised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
IL‐6: Regulator of Treg/Th17 balance
Kimura, A., & Kishimoto, T. (2010) · European Journal of Immunology · doi:10.1002/eji.201040391 · Cited by 1,595
(2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-79 · Cited by 1,506
Physiological Roles of Aquaporin-4 in Brain
Nagelhus, E. A., & Ottersen, O. P. (2013) · Physiological Reviews · doi:10.1152/physrev.00011.2013 · Cited by 766
Chihara, N., Aranami, T., Sato, W., Miyazaki, Y., Miyake, S., Okamoto, T., Ogawa, M., Toda, T., & Yamamura, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017385108 · Cited by 474
Self-citationKitley, J., Leite, M. I., Nakashima, I., Waters, P., McNeillis, B., Brown, R., Takai, Y., Takahashi, T., Misu, T., Elsone, L., et al. (2012) · Brain · doi:10.1093/brain/aws109 · Cited by 438
Self-citationIgawa, T., Ishii, S., Tachibana, T., Maeda, A., Higuchi, Y., Shimaoka, S., Moriyama, C., Watanabe, T., Takubo, R., Doi, Y., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1691 · Cited by 353
Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6
Uzawa, A., Mori, M., Arai, K., Sato, Y., Hayakawa, S., Masuda, S., Taniguchi, J., & Kuwabara, S. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510379247 · Cited by 323
Neuromyelitis Spectrum Disorders
Weinshenker, B. G., & Wingerchuk, D. M. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.12.014 · Cited by 286
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies
Papadopoulos, M. C., Bennett, J. L., & Verkman, A. S. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.141 · Cited by 262
Reichert, J. M. (2017) · mAbs · doi:10.1080/19420862.2016.1269580 · Cited by 244
Matsushita, T., Tateishi, T., Isobe, N., Yonekawa, T., Yamasaki, R., Matsuse, D., Murai, H., & Kira, J.-I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061835 · Cited by 219
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus
Sepúlveda, M., Armangué, T., Solà‐Valls, N., Arrambide, G., Meca-Lallana, J. E., Oreja‐Guevara, C., Mendibe, M., de Arcaya, A. Á., Aladro, Y., Casanova, B., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000225 · Cited by 160
Self-citationPhysiological effects of modulating the interleukin-6 axis
Schett, G. A. (2018) · Rheumatology · doi:10.1093/rheumatology/kex513 · Cited by 159
Pain in neuromyelitis optica and its effect on quality of life: A cross-sectional study
Kanamori, Y., Nakashima, I., Takai, Y., Nishiyama, S., Kuroda, H., Takahashi, T., Kanaoka, C., Misu, T., Fujihara, K., & Itoyama, Y. (2011) · Neurology · doi:10.1212/wnl.0b013e318229e694 · Cited by 135
Self-citationPresent and Future Therapies in Neuromyelitis Optica Spectrum Disorders
Kleiter, I., & Gold, R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0400-8 · Cited by 120
Self-citationJackson, D., White, I. R., Seaman, S. R., Evans, H., Baisley, K. J., & Carpenter, J. R. (2014) · Statistics in Medicine · doi:10.1002/sim.6274 · Cited by 91
Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System
Oh, J., & Levy, M. (2012) · Neurology Research International · doi:10.1155/2012/460825 · Cited by 86
Barros, P. O., Cassano, T., Hygino, J., Ferreira, T. B., Centurião, N., Kasahara, T. M., Andrade, R. M., Linhares, U. C., Andrade, A. F. B., Vasconcelos, C. C. F., et al. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12733 · Cited by 86
The Treatment of Neuromyelitis Optica
Kowarik, M. C., Soltys, J. N., & Bennett, J. L. (2014) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000102 · Cited by 53
Th17 cells in neuromyelitis optica spectrum disorder: a review
Lin, J., Li, X., & Xia, J. (2016) · International Journal of Neuroscience · doi:10.3109/00207454.2016.1163550 · Cited by 53
Sensitivity to censored‐at‐random assumption in the analysis of time‐to‐event endpoints
Lipkovich, I. A., Ratitch, B., & O’Kelly, M. (2016) · Pharmaceutical Statistics · doi:10.1002/pst.1738 · Cited by 50
Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica
Akaishi, T., Nakashima, I., Misu, T., Fujihara, K., & Aoki, M. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.05.007 · Cited by 48
Self-citationHsu, C., & Taylor, J. M. G. (2008) · Statistics in Medicine · doi:10.1002/sim.3480 · Cited by 23
Seok, J., Cho, E., Lee, H., Cho, H., Min, J.-H., Lee, K., & Kim, B. (2016) · Journal of Neurological Sciences · doi:10.1016/j.jns.2016.06.030 · Cited by 10
Neuromyelitis optica spectrum disorders: beyond longitudinally extensive transverse myelitis
Lemos, M. D., Carvalho, G. B. S., de Carvalho, R. S., Bichuetti, D. B., de Oliveira, E. M. L., & Abdala, N. (2015) · Clinical Radiology · doi:10.1016/j.crad.2015.02.016 · Cited by 9
Cited by
Myelin-oligodendrocyte glycoprotein antibody-associated disease
Marignier, R., Hacohen, Y., Cobo-Calvo, A., Pröbstel, A.-K., Aktas, O., Alexopoulos, H., Amato, M.-P., Asgari, N., Banwell, B., Bennett, J., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00218-0 · Cited by 543
Self-citationTraboulsee, A., Greenberg, B. M., Bennett, J. L., Szczechowski, L., Fox, E., Shkrobot, S., Yamamura, T., Terada, Y., Kawata, Y., Wright, P., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30078-8 · Cited by 513
Self-citationJarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 478
Kaplon, H., Muralidharan, M., Schneider, Z., & Reichert, J. M. (2020) · mAbs · doi:10.1080/19420862.2019.1703531 · Cited by 429
Tahara, M., Oeda, T., Okada, K., Kiriyama, T., Ochi, K., Maruyama, H., Fukaura, H., Nomura, K., Shimizu, Y., Mori, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30066-1 · Cited by 378
Metadata
- Authors
- Yamamura, T., Kleiter, I., Fujihara, K., Palace, J., Greenberg, B., Zakrzewska-Pniewska, B., Patti, F., Tsai, C.-P., Saiz, A., Yamazaki, H., Kawata, Y., Wright, P., & De Seze, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-11-28
- Volume
- 381
- Issue
- 22
- Pages
- 2114-2124
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2991438804
- Cited by
- 664
- References
- 28
- FWCI
- 45.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.